Changjiang Health and its controlling shareholder were filed, Li Yan, former director and president of Hisun Pharmaceutical, was investigated, and Wohua Pharmaceutical was fined 500,000 yuan丨Listed pharmaceutical company tracking

@关于医药上市公司预警: Daan Gene will have a net loss of 363 million yuan in the first quarter of 2024, Dizhe Pharmaceutical will have a net loss of 1.108 billion yuan in 2023, Junshi Biosciences will have a net loss of 283 million yuan in the first quarter of 2024, Bio-Thera will have a net loss of 119 million yuan in the first quarter of 2024, Zhaoyan New Drug will have a net loss of 272 million yuan in the first quarter of 2024, Dongfang Biotech will have a net loss of 67.35 million yuan in the first quarter of 2024, Meinian Health will have a net loss of 287 million yuan in the first quarter of 2024, and ST Zhongzhu will have a net loss of 22.8936 million yuan in the first quarter of 2024Mabwell's net loss in the first quarter of 2024 was 206 million yuan, Yahong Pharmaceutical's net loss in the first quarter of 2024 was 82.85 million yuan, Shuangcheng Pharmaceutical's net loss in 2023 was 50.7416 million yuan, China Resources Sanjiu's independent directors resigned, Changjiang Health Company and its controlling shareholder were filed, and Xinghao Pharmaceutical's shareholders planned to reduce their holdings by no more than 1.51% Li Yan, former director and president of Hisun Pharmaceutical, is under investigation by relevant departments, Saili Medical is still under investigation on suspicion of illegal information disclosure, and Wohua Pharmaceutical has received the Administrative Penalty Decision.

@关于医药上市公司动态: In terms of performance, East Asia Pharmaceutical, Dabo Medical, Mingde Biotechnology, Shangrong Medical, China Pharmaceutical, Haohai Biotechnology, ST Kangmei, Xuantai Pharmaceutical, Jinling Pharmaceutical, Miracle Pharmaceutical, Lianhuan Pharmaceutical, Fosun Pharmaceutical, First Pharmaceutical, Fudan Zhangjiang, Hepalink, Jiankai Technology, Menova, Stellite, Hotgen Biotechnology, Rendu Biotechnology, Xinhua Medical, Laobaimin, Senxuan Pharmaceutical, Kemei Diagnostics, Zhenbaodao, Yirui Technology, Weigao Orthopedics, In terms of clinical/R&D/market progress, New Industry, China Resources Shuanghe, Huahai Pharmaceutical, Sanxin Medical, Lingkang Pharmaceutical and Nhwa Pharmaceutical have all made progress, in terms of share pledge/reduction/repurchase, Gan & Lee Pharmaceutical, Sialon Pharmaceutical, Jinyu Medical, Yongan Pharmaceutical and Jiu'an Medical have new trends, and Mindray Medical has acquired control of Huitai Medical.

Early warning on listed pharmaceutical companies

Daan Gene: Net loss of 363 million yuan in the first quarter of 2024

Daan Gene released a first-quarter performance announcement on the evening of April 29, saying that the revenue in the first quarter of 2024 will be about 198 million yuan, a year-on-year decrease of 41.85%, the net profit loss attributable to shareholders of listed companies will be about 363 million yuan, and the basic earnings per share loss will be 0.2589 yuan.

Dizhe Pharmaceutical: Net loss of 1.108 billion yuan in 2023

Dizhe Pharmaceutical released its annual performance report on the evening of April 29, saying that its operating income in 2023 will be about 91.29 million yuan, the net profit loss attributable to shareholders of listed companies will be about 1.108 billion yuan, and the basic earnings per share loss will be 2.72 yuan. In the same period of 2022, the net profit loss attributable to shareholders of the listed company was about 736 million yuan, and the basic earnings per share loss was 1.82 yuan.

Junshi Biosciences: Net profit in the first quarter of 2024 will be about -283 million yuan

Junshi Biosciences released its first-quarter results announcement on the evening of April 29, saying that the revenue in the first quarter of 2024 will be about 381 million yuan, an increase of 49.24% year-on-year, the net profit loss attributable to shareholders of the listed company will be about 283 million yuan, and the basic earnings per share loss will be 0.29 yuan.

Bio-Thera: Net loss of 119 million yuan in the first quarter of 2024

Bio-Thera announced its first-quarter results on the evening of April 29, saying that its revenue in the first quarter of 2024 will be about 162 million yuan, an increase of 4.3% year-on-year, the net profit loss attributable to shareholders of listed companies will be about 119 million yuan, and the basic earnings per share loss will be 0.29 yuan.

Zhaoyan New Drug: Net loss of 272 million yuan in the first quarter of 2024

Zhaoyan New Drug released a first-quarter performance announcement on the evening of April 29, saying that the company achieved revenue of 325 million yuan during the reporting period, a year-on-year decrease of 12.07%, a net profit loss of 272 million yuan attributable to the parent company, and a non-net profit loss of 281 million yuan. Basic earnings per share was -0.36 yuan.

Dongfang Biotech: Net loss of 67.35 million yuan in the first quarter of 2024

Dongfang Biotech released a first-quarter results announcement on the evening of April 29, saying that the revenue in the first quarter of 2024 will be about 183 million yuan, a year-on-year decrease of 51.36%, the net profit loss attributable to shareholders of listed companies will be about 67.35 million yuan, a year-on-year decrease of 33.82%, and the basic earnings per share loss will be 0.33 yuan, a year-on-year decrease of 10%.

Meinian Health: Net loss of 287 million yuan in the first quarter of 2024

Meinian Health announced its first-quarter results on April 29, saying that the total operating income in the reporting period was 1.801 billion yuan, a year-on-year decrease of 14.91%, a net loss of 287 million yuan, a year-on-year increase of 66.67%, and basic earnings per share of -0.07 yuan.

ST Zhongzhu: The net loss in the first quarter of 2024 was 22.8936 million yuan

ST Zhongzhu released a first-quarter performance announcement on the evening of April 29, saying that the total operating income in the reporting period was 130 million yuan, a year-on-year increase of 10.34%, a net loss of 22.8936 million yuan, a year-on-year decrease of 17.73%, and the basic earnings per share was -0.01 yuan.

Mabwell: Net loss of 206 million yuan in the first quarter of 2024

Mabwell released its first-quarter results announcement on the evening of April 29, saying that its revenue in the first quarter of 2024 was about 67.56 million yuan, an increase of 1572.42% year-on-year, the net profit loss attributable to shareholders of the listed company was about 206 million yuan, and the basic earnings per share loss was 0.51 yuan.

Yahong Pharmaceutical: Net loss of 82.85 million yuan in the first quarter of 2024

Yahong Pharmaceutical announced its first-quarter results on the evening of April 29, saying that its revenue in the first quarter of 2024 will be about 24.32 million yuan, an increase of 106,217.71% year-on-year, the net profit loss attributable to shareholders of listed companies will be about 82.85 million yuan, and the basic earnings per share loss will be 0.15 yuan.

Shuangcheng Pharmaceutical: Net loss of 50.7416 million yuan in 2023

Shuangcheng Pharmaceutical announced on April 29 that it will achieve a total operating income of 236 million yuan in 2023, a year-on-year decrease of 14.13%, a net loss of 50.7416 million yuan, a year-on-year profit of 9.0124 million yuan, and a basic earnings per share of -0.12 yuan.

China Resources Sanjiu: Independent directors resigned

China Resources Sanjiu announced on April 29 that it had recently received a resignation report submitted by Academician Zhang Qiang, an independent director, and that according to the relevant regulations on the part-time management of academicians of the Chinese Academy of Engineering, Academician Zhang Qiang submitted his resignation as an independent director of the eighth board of directors of the company and a member of the remuneration and assessment committee of the board of directors. After his resignation, Academician Zhang Qiang no longer holds a position in the Company. As of the date of this announcement, Academician Zhang Qiang does not hold shares of the company, and there are no commitments that should be fulfilled but not fulfilled.

Changjiang Health: The company and its controlling shareholder were filed

Changjiang Health announced on April 29 that the company and its controlling shareholder, Changjiang Runfa Group, recently received the "Notice of Case Filing from the China Securities Regulatory Commission" issued by the China Securities Regulatory Commission. In accordance with the Securities Law of the People's Republic of China, the Administrative Punishment Law of the People's Republic of China and other laws and regulations, the China Securities Regulatory Commission decided to file a case against Changjiang Health and Changjiang Runfa Group on suspicion of illegal information disclosure.

Xinghao Pharmaceutical: Shareholders plan to reduce their holdings by no more than 1.51%.

Xinghao Pharmaceutical announced on April 29 that its shareholder Beijing Shuanglu Pharmaceutical Co., Ltd. intends to reduce its holdings of the company's shares by no more than 1.85 million shares, and the reduction ratio will not exceed 1.51% of the company's total share capital.

Hisun Pharmaceutical: Li Yan, former director and president, was investigated by relevant departments

Hisun Pharmaceutical announced on April 29 that the company received a letter from the State-owned Assets Supervision and Administration Office of the People's Government of Jiaojiang District, Taizhou City, that Li Yan, the former director and former president of the company, was suspected of embezzlement, embezzlement, bribery, and bribery of non-state employees in the company's agency business from 2019 to 2022, and the relevant departments are currently in the process of investigation.

Hisun Pharmaceutical said that Li Yan has resigned as a director and president of the company on April 5, 2023, and will no longer hold any position in the company and its subsidiaries after his resignation. At present, the company's production and operation order is normal, various businesses are progressing steadily, and daily production and operation activities have not been affected.

On the same day, Hisun Pharmaceutical announced that the company's board of directors held the 27th meeting of the ninth board of directors on April 26, 2024, and deliberated and passed the "Proposal on the Appointment of the Company's Senior Managers". According to the proposal, Mr. Jiang Ling was appointed as the senior vice president and chief financial officer of the company after being nominated by the president of the company and approved by the board of directors, and his term of office will end at the end of the current board of directors.

In terms of performance, the operating income in 2023 was 10.373 billion yuan, a year-on-year decrease of 1.664 billion yuan, and the net profit attributable to the owners of the parent company in 2023 was -93 million yuan, a year-on-year decrease of 582 million yuan, of which the net profit attributable to the owners of the parent company after deducting non-recurring gains and losses was -100 million yuan, a decrease of 413 million yuan compared with 2022.

In addition, at the end of 2023, Sun Company Hui Zheng received a "Notice of Termination Notice" from Fudan Zhangjiang, informing him that the "Marketing Service Agreement" on Libaoduo would be terminated from December 31, 2023. After receiving the above-mentioned letter, Huizheng held several rounds of negotiations with Fudan Zhangjiang, and the two sides no longer had the possibility of reaching a consensus to continue to promote cooperation. As of the disclosure date of this announcement, the two parties are still conducting data verification and communication negotiations on follow-up matters such as the settlement of promotion fees after the termination of marketing cooperation.

Saili Medical: The investigation of suspected illegal information disclosure is still ongoing

Seili Medical announced on April 29 that the company received the Notice of Case Filing from the China Securities Regulatory Commission (hereinafter referred to as the "China Securities Regulatory Commission") on March 25, 2024 (No. 0052024002). Up to now, the company's production and operation activities have been carried out normally. The CSRC's investigation is ongoing, and the Company has not yet received a conclusive opinion or decision on the above-mentioned matters under investigation. During the investigation period, the company will actively cooperate with the investigation of the China Securities Regulatory Commission, and in strict accordance with the relevant provisions of the "Shanghai Stock Exchange Stock Listing Rules", disclose the risk warning announcement once a month to explain the progress of the investigation.

Wohua Pharmaceutical: Received the "Administrative Penalty Decision"

Wohua Pharmaceutical announced on April 29 that on April 28, 2024, the company received the "Administrative Penalty Decision" ([2024] No. 1) issued by the Shandong Supervision Bureau of the China Securities Regulatory Commission. According to the Shandong Supervision Bureau, after investigation, Zhao Bingxian, the actual controller and chairman of Wohua Pharmaceutical Pharmaceutical, was placed in custody by the Yangxin County Supervision Commission from July 13, 2023 to November 21, 2023 on suspicion of violating the law and committing crimes on duty, and the retention in custody measures had an impact on his performance of duties. Wohua Pharmaceutical's failure to disclose in a timely manner that Zhao Bingxian was subject to retention in custody was unlawful. The Shandong Supervision Bureau decided to order Shandong Wohua Pharmaceutical Technology Co., Ltd. to make corrections, give a warning and impose a fine of 500,000 yuan, and give Zhao Caixia a warning and impose a fine of 200,000 yuan.

About the dynamics of listed pharmaceutical companies

Performance

East Asia Pharmaceutical: Net profit attributable to shareholders of listed companies in the first quarter of 2024 was 24.03 million yuan

East Asia Pharmaceutical released a report for the first quarter of 2024 on April 29, saying that in the first quarter of 2024, the company achieved a net profit attributable to shareholders of listed companies of 24,039,198.04 yuan, a year-on-year increase of 3.53%.

Dabo Medical: net profit in the first quarter was 61.7289 million yuan

Dabo Medical released a first-quarter report on the evening of April 29, saying that the net profit attributable to the owners of the parent company in the first quarter was 61.7289 million yuan, a year-on-year increase of 6.05%, the operating income was 427 million yuan, a year-on-year increase of 9.17%, and the basic earnings per share was 0.15 yuan, a year-on-year increase of 7.14%.

Mingde Biotech: net profit in the first quarter was 32.0521 million yuan

Mingde Biotech announced the first quarter of 2024 report on April 29, saying that the operating income in the reporting period was 60.9634 million yuan, a year-on-year decrease of 83.63%, the net profit attributable to shareholders of listed companies was 32.0521 million yuan, a year-on-year decrease of 57.52%, and the basic earnings per share was 0.14 yuan.

Shangrong Medical: The net profit in the first quarter of 2024 will be about 13.88 million yuan, an increase of 97.44% year-on-year

Shangrong Medical announced its first-quarter results on the evening of April 29, saying that the revenue in the first quarter of 2024 was about 276 million yuan, a year-on-year decrease of 10.75%, the net profit attributable to shareholders of listed companies was about 13.88 million yuan, an increase of 97.44% year-on-year, and the basic earnings per share was 0.02 yuan, an increase of 100% year-on-year.

China Pharmaceutical: Net profit in the first quarter of 2024 was 146 million yuan

China Pharmaceutical released a first-quarter report on April 29, saying that the total operating income in the reporting period was 8.775 billion yuan, down 29.97% year-on-year, and the net profit was 146 million yuan, down 45.83% year-on-year, and the basic earnings per share was 0.10 yuan.

Haohaishengke: The net profit in the first quarter of 2024 will be about 97.54 million yuan

Haohaishengke released the first quarter results announcement on the evening of April 29, saying that the revenue in the first quarter of 2024 will be about 646 million yuan, an increase of 5.68% year-on-year, the net profit attributable to shareholders of listed companies will be about 97.54 million yuan, an increase of 20.16% year-on-year, and the basic earnings per share will be 0.58 yuan, an increase of 23.4% year-on-year.

ST Kangmei: net profit in the first quarter was 7.4713 million yuan

ST Kangmei announced the first quarter results on April 29, saying that during the reporting period, the company achieved operating income of 1.201 billion yuan, an increase of 5.01% year-on-year, net profit attributable to shareholders of listed companies of 7.4713 million yuan, net loss attributable to shareholders of listed companies after deducting non-recurring gains and losses of 58.4765 million yuan, and basic earnings per share of 0.001 yuan.

Xuantai Pharmaceutical: Net profit in the first quarter of 2024 will be about 22.9 million yuan

Xuantai Pharmaceutical announced its first-quarter results on April 29, saying that its revenue in the first quarter of 2024 was about 111 million yuan, an increase of 162.65% year-on-year, and the net profit attributable to shareholders of listed companies was about 22.9 million yuan, an increase of 196.71% year-on-year.

Jinling Pharmaceutical: The net profit in the first quarter of 2024 will be about 43.54 million yuan

Jinling Pharmaceutical released a first-quarter results announcement on the evening of April 29, saying that the revenue in the first quarter of 2024 was about 747 million yuan, an increase of 5.36% year-on-year, the net profit attributable to shareholders of listed companies was about 43.54 million yuan, a year-on-year decrease of 0.09%, and the basic earnings per share was 0.0849 yuan, a year-on-year decrease of 1.85%.

Miracle Pharmaceutical: Net profit in 2023 will be 57.0007 million yuan

Miracle Pharmaceutical released its 2023 annual performance report on April 29, saying that during the reporting period, the company achieved operating income of 2.341 billion yuan, a year-on-year decrease of 2%, a net profit attributable to shareholders of listed companies of 57.0007 million yuan, an increase of 17.41% year-on-year, a net profit attributable to shareholders of listed companies after deducting non-recurring gains and losses of 49.104 million yuan, an increase of 0.84% year-on-year, and basic earnings per share of 0.11 yuan. The company intends to distribute a cash dividend of 1 yuan to all shareholders for every 10 shares.

Lianhuan Pharmaceutical: net profit of 32.55 million yuan in the first quarter

Lianhuan Pharmaceutical announced the first quarter report of 2024 on April 29, with revenue of 528 million yuan, a year-on-year increase of 17%, a net profit attributable to the parent company of 32.55 million yuan, a year-on-year increase of 4.58%, and a non-net profit of 30.74 million yuan, a year-on-year increase of 5.31%. Basic earnings per share was 0.11 yuan.

Fosun Pharma: net profit of 610 million yuan in the first quarter

Fosun Pharma disclosed its quarterly report on the evening of April 29, the company's operating income in the first quarter of 2024 was 10.157 billion yuan, down 6.56% year-on-year, net profit was 610 million yuan, down 38.22% year-on-year, and basic earnings per share was 0.23 yuan. During the reporting period, the revenue of new crown-related products fell significantly.

First Pharmaceutical: The net profit in the first quarter of 2024 was 36.0538 million yuan

First Pharmaceutical announced its first-quarter results on April 29, saying that it achieved a total operating income of 462 million yuan in the reporting period, a year-on-year increase of 0.65%, a net profit of 36.0538 million yuan, a year-on-year increase of 21.75%, and basic earnings per share of 0.16 yuan.

Fudan Zhangjiang: Net profit in the first quarter of 2024 will be about 2.35 million yuan

Fudan Zhangjiang announced its first-quarter results on the evening of April 29, saying that the revenue in the first quarter of 2024 was about 148 million yuan, a year-on-year decrease of 21.94%, and the net profit attributable to shareholders of listed companies was about 2.35 million yuan, a year-on-year decrease of 73.29%.

Hepalink: Net profit in the first quarter of 2024 will be about 155 million yuan, an increase of 133% year-on-year

Hepalink announced its first-quarter results on the evening of April 29, saying that the revenue in the first quarter of 2024 will be about 1.373 billion yuan, an increase of 5.55% year-on-year, the net profit attributable to shareholders of listed companies will be about 155 million yuan, an increase of 133% year-on-year, and the basic earnings per share will be 0.1057 yuan, an increase of 133.33% year-on-year.

Jiankai Technology: Net profit in 2023 will be about 116 million yuan, a year-on-year decrease of 38.05%

Jiankai Technology released its annual performance report on the evening of April 29, saying that the operating income in 2023 will be about 292 million yuan, a year-on-year decrease of 28.26%, the net profit attributable to shareholders of listed companies will be about 116 million yuan, a year-on-year decrease of 38.05%, and the basic earnings per share will be 1.92 yuan, a year-on-year decrease of 38.26%.

Menova: Net profit in the first quarter of 2024 will be about 14.04 million yuan

Menova announced its first-quarter results on the evening of April 29, saying that its revenue in the first quarter of 2024 was about 263 million yuan, an increase of 6.68% year-on-year, the net profit attributable to shareholders of listed companies was about 14.04 million yuan, a year-on-year decrease of 67.68%, and the basic earnings per share was 0.07 yuan, a year-on-year decrease of 66.67%.

Stellite: The net profit in the first quarter of 2024 will be about 12.28 million yuan

Stellite announced its first-quarter results on the evening of April 29, saying that the revenue in the first quarter of 2024 will be about 642 million yuan, an increase of 13.5% year-on-year, the net profit attributable to shareholders of listed companies will be about 12.28 million yuan, an increase of 28.37% year-on-year, and the basic earnings per share will be 0.04 yuan, an increase of 33.33% year-on-year.

Hotgen Biotech: The net profit in the first quarter of 2024 will be about 5.05 million yuan

Hotgen Biotech released a first-quarter results announcement on the evening of April 29, saying that the revenue in the first quarter of 2024 will be about 116 million yuan, a year-on-year decrease of 42.78%, the net profit attributable to shareholders of listed companies will be about 5.05 million yuan, a year-on-year decrease of 91.42%, and the basic earnings per share will be 0.06 yuan, a year-on-year decrease of 90.91%.

Rendu Bio: Net profit in 2023 will be about 8.26 million yuan, a year-on-year decrease of 64.6%

Rendu Biotech released its annual performance report on April 29, saying that the operating income in 2023 will be about 164 million yuan, a year-on-year decrease of 45.89%, the net profit attributable to shareholders of listed companies will be about 8.26 million yuan, a year-on-year decrease of 64.6%, and the basic earnings per share will be 0.21 yuan, a year-on-year decrease of 66.13%.

Xinhua Medical: net profit in the first quarter was 211 million yuan

Xinhua Medical announced its first-quarter results on April 29, saying that it achieved operating income of 2.529 billion yuan, a year-on-year increase of 3.68%, net profit attributable to shareholders of listed companies of 211 million yuan, a year-on-year increase of 7.39%, net profit attributable to shareholders of listed companies after deducting non-recurring gains and losses of 209 million yuan, a year-on-year increase of 13.77%, and basic earnings per share of 0.45 yuan.

People: net profit in the first quarter was 321 million yuan

On April 29, the company announced the first quarter results, saying that during the reporting period, the company achieved operating income of 5.539 billion yuan, an increase of 1.81% year-on-year, net profit attributable to shareholders of listed companies of 321 million yuan, an increase of 10.27% year-on-year, net profit attributable to shareholders of listed companies after deducting non-recurring gains and losses of 311 million yuan, an increase of 10.35% year-on-year, and basic earnings per share of 0.55 yuan.

Senxuan Pharmaceutical: The net profit in the first quarter of 2024 was 34.8618 million yuan

Senxuan Pharmaceutical announced its first-quarter results on April 29, saying that the total operating income in the reporting period was 138 million yuan, a year-on-year decrease of 21.40%, and the net profit was 34.8618 million yuan, a year-on-year decrease of 23.21%, and the basic earnings per share was 0.08 yuan.

Chemclin Diagnostics: Net profit in 2023 will be about 147 million yuan

Kemei Diagnostics released its annual performance report on the evening of April 29, saying that the operating income in 2023 will be about 445 million yuan, a year-on-year decrease of 4.28%, the net profit attributable to shareholders of listed companies will be about 147 million yuan, a year-on-year decrease of 3.44%, and the basic earnings per share will be 0.37 yuan, a year-on-year decrease of 2.63%.

Zhenbaodao: net profit in 2023 will be about 473 million yuan, an increase of 154.93% year-on-year

Zhenbaodao released its annual performance report on the evening of April 29, saying that the operating income in 2023 will be about 3.138 billion yuan, a year-on-year decrease of 25.53%, the net profit attributable to shareholders of listed companies will be about 473 million yuan, an increase of 154.93% year-on-year, and the basic earnings per share will be 0.5032 yuan, an increase of 155.43% year-on-year.

Yirui Technology: The net profit in the first quarter was 139 million yuan

Yirui Technology released a first-quarter performance announcement on the evening of April 29, saying that the company's operating income was 491 million yuan, a year-on-year increase of 11.48%. net profit attributable to shareholders of listed companies was 139 million yuan, a year-on-year increase of 1.88%. net profit attributable to shareholders of listed companies after deducting non-recurring gains and losses was 156 million yuan, a year-on-year increase of 6%. Basic earnings per share was 1.37 yuan.

Weigao Orthopedics: The net profit in the first quarter of 2024 will be about 34.91 million yuan

Weigao Orthopedics announced its first-quarter results on the evening of April 29, saying that the revenue in the first quarter of 2024 was about 348 million yuan, a year-on-year decrease of 10.74%, the net profit attributable to shareholders of listed companies was about 34.91 million yuan, a year-on-year decrease of 62.92%, and the basic earnings per share was 0.09 yuan, a year-on-year decrease of 62.5%.

Humanwell Pharmaceutical: net profit in the first quarter was about 486 million yuan

Humanwell Pharmaceutical announced the first quarter results on April 29, saying that the company's operating income during the reporting period was about 6.367 billion yuan, a year-on-year increase of 2.28%, and the corresponding attributable net profit was about 486 million yuan, a year-on-year decrease of 26.89%.

Tianxin Pharmaceutical: net profit of 148 million yuan in the first quarter, a year-on-year increase of 35.87%

Tianxin Pharmaceutical released a report for the first quarter of 2024 on April 29, saying that it achieved operating income of 494 million yuan, a year-on-year decrease of 14.46%, a net profit attributable to shareholders of listed companies of 148 million yuan, a year-on-year increase of 35.87%, a net profit attributable to shareholders of listed companies after deducting non-recurring gains and losses of 136 million yuan, a year-on-year increase of 33.53%, and basic earnings per share of 0.34 yuan.

WuXi AppTec: net profit in the first quarter was 1.942 billion yuan

WuXi AppTec disclosed its first quarter report for 2024 on April 29, with operating income of RMB7.982 billion, down 10.95% year-on-year, net profit attributable to the parent company of RMB1.942 billion, down 10.42% year-on-year, and basic earnings per share of RMB0.67.

Essence Pharmaceutical: Net profit in the first quarter of 2024 will be about 71.08 million yuan, a year-on-year decrease of 18.92%

Essence Pharmaceutical announced its first-quarter results on April 29, saying that its revenue in the first quarter of 2024 was about 367 million yuan, a year-on-year decrease of 11.82%, the net profit attributable to shareholders of listed companies was about 71.08 million yuan, a year-on-year decrease of 18.92%, and the basic earnings per share was 0.0873 yuan, a year-on-year decrease of 18.94%.

Anxu Biotech: The net profit in the first quarter of 2024 will be about 70.19 million yuan

Anxu Biotech announced its first-quarter results on April 29, saying that the revenue in the first quarter of 2024 was about 129 million yuan, an increase of 6.53% year-on-year, the net profit attributable to shareholders of listed companies was about 70.19 million yuan, an increase of 38.09% year-on-year, and the basic earnings per share was 0.55 yuan, an increase of 38.09% year-on-year.

Wanbangde: net profit in the first quarter was 28.8385 million yuan

Wanbond announced the first quarter results on April 29, saying that during the reporting period, the company achieved operating income of 429 million yuan, a year-on-year increase of 11.41%, net profit attributable to shareholders of listed companies of 28.8385 million yuan, a year-on-year increase of 5.49%, net profit attributable to shareholders of listed companies after deducting non-recurring gains and losses of 14.0973 million yuan, a year-on-year decrease of 43.19%, and basic earnings per share of 0.0466 yuan/share.

Guangyuyuan: The net profit in 2023 will be 90.0786 million yuan

Guangyuyuan announced on April 29 that the company's operating performance improved significantly in the first full fiscal year after the state-owned assets became the owner. In 2023, the company will achieve an operating income of 1.284 billion yuan, a year-on-year increase of 13.56%, and its performance will turn losses into profits, achieving a net profit attributable to the parent company of 90.0786 million yuan.

Bloomage Biotech: Net profit in 2023 will be 593 million yuan

Bloomage Biotech announced on April 29 that in 2023, the company's revenue will be 6.076 billion yuan, net profit will be 593 million yuan, and net profit will be 490 million yuan after deducting non-recurring gains and losses.

Yuekang Pharmaceutical: The net profit in the first quarter of 2024 will be about 69.31 million yuan

Yuekang Pharmaceutical announced its first-quarter results on April 29, saying that its revenue in the first quarter of 2024 was about 968 million yuan, a year-on-year decrease of 14.24%, the net profit attributable to shareholders of listed companies was about 69.31 million yuan, a year-on-year decrease of 18.72%, and the basic earnings per share was 0.15 yuan, a year-on-year decrease of 21.05%.

ST Nanwei: Net profit in the first quarter of 2024 will be about 1.75 million yuan

ST Nanwei released a first-quarter results announcement on the evening of April 29, saying that the revenue in the first quarter of 2024 will be about 139 million yuan, a year-on-year decrease of 38.45%, the net profit attributable to shareholders of listed companies will be about 1.75 million yuan, a year-on-year decrease of 74.82%, and the basic earnings per share will be 0.006 yuan, a year-on-year decrease of 75%.

Zhejiang Zhenyuan: The net profit in the first quarter of 2024 will be about 19.25 million yuan

Zhejiang Zhenyuan released a first-quarter performance announcement on the evening of April 29, saying that the revenue in the first quarter of 2024 will be about 1.045 billion yuan, a year-on-year decrease of 4.87%, the net profit attributable to shareholders of listed companies will be about 19.25 million yuan, an increase of 3.67% year-on-year, and the basic earnings per share will be 0.0576 yuan, an increase of 3.6% year-on-year.

Clinical/R&D/Market Progress

New industry: Obtained patent certificate

New Industry announced on the evening of April 29 that Shenzhen New Industry Biomedical Engineering Co., Ltd. recently received three "Invention Patent Certificates" issued by the State Intellectual Property Office. The patent names are "chemiluminescence detector, incubation device and incubation method thereof", "thin sheet media capping equipment" and so on.

China Resources Shuanghe: The marketing application of the API of the holding subsidiary Bunanserin was approved

China Resources Shuanghe announced on April 29 that recently, the company's holding subsidiary, Hunan Xiangzhong Pharmaceutical Co., Ltd., received the "Notice of Approval of Marketing Application for Chemical APIs" issued by the State Drug Administration. Blonamserin is a new second-generation antipsychotic used to treat schizophrenia. By antagonizing the D2 receptor of DA in the limbic system of the midbrain and the A2 receptor of 5-HT (serotonin), the goal of treating positive and negative symptoms of schizophrenia, affective symptoms and cognitive impairment is achieved, while reducing extrapyramidal reactions and elevated levels of prolactin, with better efficacy and fewer adverse reactions.

Huahai Pharmaceutical: Its subsidiary obtained the clinical trial license of HB0052 for injection

Huahai Pharmaceutical announced that its subsidiaries Huaota and Huabo Biotech have obtained clinical trial approval for HB0052 for injection. HB0052 is the first third-generation antibody-drug conjugate drug based on Huaota antibody drug conjugate platform that targets CD73 antigen with topoisomerase inhibitor as the load. The ADC molecule can exert antibody-mediated immune system regulation function and toxic small molecule killing function on tumor cells at the same time, and has a synergistic anti-tumor effect. Preclinical animal model studies have shown that HB0052 has excellent anti-tumor efficacy, preclinical pharmacokinetic results in non-human primates have shown that HB0052 has linear pharmacokinetic characteristics, good plasma stability, low non-specific shedding levels, long half-life and satisfactory pharmacokinetic properties, and toxicological studies have shown that HB0052 is safe and well tolerated. At present, CD73-targeting drugs at home and abroad have not been marketed. There are a number of monoclonal antibody projects in the clinical research stage, and the indications developed are non-small cell lung cancer, breast cancer, pancreatic cancer, prostate cancer and other solid tumors.

On the same day, Huahai Pharmaceutical released its performance report for the first quarter of 2024. During the reporting period, the total operating income was 2.499 billion yuan, a year-on-year increase of 21.36%, the net profit was 271 million yuan, a year-on-year increase of 56.62%, and the basic earnings per share was 0.19 yuan.

Sanxin Medical: The product "hemodialysis concentrate" obtained the registration certificate

Sanxin Medical announced on April 29 that the company has recently obtained the "Medical Device Registration Certificate" issued by the State Drug Administration. The product name is "Hemodialysis Concentrate".

Lingkang Pharmaceutical: The clinical trial application of esomeprazole magnesium sodium bicarbonate dry suspension (I) has obtained the notice of acceptance

Lingkang Pharmaceutical announced on April 29 that its wholly-owned subsidiary, Lingkang Pharmaceutical, recently obtained the "Notice of Acceptance" issued by the Center for Drug Evaluation (CDE) of the National Medical Products Administration for the registration of clinical trials for the domestic production of esomeprazole magnesium sodium bicarbonate dry suspension (I).

Nhwa Pharmaceutical: Alfentanil hydrochloride injection was approved for drug supplemental application

Nhwa Pharmaceutical announced on the evening of April 29 that the company recently received the approval notice of the drug supplement application for alfentanil hydrochloride injection approved by the State Drug Administration, and approved the drug to increase the specification by 5ml: 2.5mg. Alfentanil hydrochloride injection is an opioid receptor agonist used as a narcotic analgesic for general anesthesia induction and maintenance.

Share pledge/reduction/repurchase

Gan & Lee Pharmaceutical: More than 5% of the shareholders Xute Hongda pledged shares

Gan & Lee Pharmaceutical announced on April 29 that Beijing Xute Hongda Technology Co., Ltd. (hereinafter referred to as "Xute Hongda") holds 47.4944 million shares of Gan & Lee Pharmaceutical's unrestricted tradable shares, accounting for 7.99% of the company's total share capital. After the share pledge, the cumulative number of shares pledged by Xute Hongda is 10.9 million shares, accounting for 22.95% of its holdings and 1.83% of the company's total share capital.

Sialon Pharmaceutical: The controlling shareholder released the pledge of 18 million shares

Sialon Pharmaceutical announced on April 29 that Mr. Cai Nangui, the company's controlling shareholder, has released the pledge of 18 million shares, accounting for 20.00% of its shares. The pledge started on 2021.10.28, expired and released on 2024.04.26, and the pledge trustee is Western Securities Co., Ltd. Mr. Cai Nangui and Ms. Tang Lin are acting in concert, holding a total of 56.62% of the shares, of which the pledged shares have been reduced from 34 million shares to 16 million shares, accounting for 9.09% of the company's total share capital.

Jinyu Medical: The proportion of the company's shares has been repurchased through centralized bidding transactions has reached 1%

Jinyu Medical announced on April 29 that as of April 29, 2024, the company has implemented four share repurchase plans, and a total of 4.7408 million shares of the company have been repurchased through centralized bidding transactions, accounting for 1.01% of the company's total share capital. The highest repurchase price is 68.57 yuan/share, the lowest repurchase price is 38.05 yuan/share, and the total amount of funds used is 270 million yuan (excluding transaction costs such as commissions). At present, the fourth buyback program is still in the process of being implemented.

Yongan Pharmaceutical: It is planned to repurchase the company's shares for 40 million yuan to 80 million yuan

Yongan Pharmaceutical announced on April 29 that the company intends to repurchase shares for 40 million yuan to 80 million yuan for equity incentive plans or employee stock ownership plans, and the repurchase price does not exceed 8 yuan per share (inclusive). In the first quarter of 2024, the operating income was 197 million yuan, a year-on-year decrease of 36.80%, the net profit was 28.68 million yuan, a year-on-year increase of 91.42%, the non-net profit was 19.97 million yuan, a year-on-year increase of 247.61%, and the basic earnings per share was 0.0973 yuan.

Jiu'an Medical: It has completed a 1 billion yuan repurchase plan

According to the record of investor relations activities disclosed by Jiu'an Medical on April 29, the company will complete a repurchase plan of 1 billion yuan in 2023, and will release a repurchase plan of 6-1.2 billion yuan again in 2024, and has completed a repurchase amount of more than 1 billion. The meeting also mentioned that the new "O+O" model of diabetes diagnosis and care has been accelerated in about 50 cities and more than 310 hospitals across the country, with more than 220,000 caregivers. The company's U.S. subsidiary has partnered with about 60 clinics to care for approximately 15,000 patients through the new model.

Changes in shareholding

Mindray Medical: Acquired control of Huitai Medical

Mindray Medical announced on April 29 that as of the date of this announcement, Cheng Zhenghui held 12.5193 million shares of Huitai Medical, accounting for 18.72% of Huitai Medical's total share capital, and held 8.72% of voting rights. The company holds a total of 16,455,600 shares of Huitai Medical through Shenmaikong and its concerted actor Zhuhai Tongsheng, accounting for 24.61% of the total share capital of Huitai Medical, and holding 24.61% of voting rights. The reorganization of the second board of directors and board of supervisors of Huitai Medical has been completed, and the company has obtained the control of Huitai Medical.

For more information, please download the 21 Finance APP